With Trump’s Return, Pharma Trades Disagreeable Knowns For Uncertainty

 
• By Jessica Merrill
  
FDA and HHS leadership could be a concern for pharma when Donald Trump returns to the White House. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Elections

More from Legislation